Skip to main content

View full-text article in PMC

. 2017 Oct 10;8(5):405–411. doi: 10.5306/wjco.v8.i5.405

Table 3.

Univariate logistic regression analysis

			OR	95%CI for OR		P value
				Lower	Upper
Gender			2.30	1.07	4.94	0.033^a
Head site			4.07	1.53	10.83	0.005^a
Max values	LSR composite		1.55	1.27	1.89	< 0.001^a
		Erythema	3.90	1.86	8.19	< 0.001^a
		Crusting	1.85	1.18	2.92	0.008^a
		Swelling	2.24	1.50	3.35	< 0.001^a
		Vesiculation/pustulation	2.76	1.55	4.94	0.001^a
Day 2	LSR composite		1.70	1.36	2.12	< 0.001^a
		Erythema	3.83	2.05	7.17	< 0.001^a
		Vesiculation/pustulation	2.82	1.74	4.56	< 0.001^a
		Swelling	2.73	1.64	4.55	< 0.001^a
Day 3	LSR composite		1.65	1.34	2.05	< 0.001^a
		Erythema	3.90	1.86	8.19	< 0.001^a
		Vesiculation/pustulation	2.76	1.55	4.94	0.001^a
		Swelling	2.22	1.51	3.28	< 0.001^a
		Ulceration	1.72	1.06	2.79	0.028^a
Day 8	LSR composite		1.25	1.07	1.47	0.006^a
		Erythema	2.44	1.45	4.13	0.001^a
		Swelling	1.55	1.06	2.25	0.022^a
		Crusting	1.76	1.17	2.64	0.006^a
Day 15	LSR composite		1.27	1.02	1.59	0.030^a
		Erythema	1.93	1.22	3.05	0.005^a
Day 29		Erythema	2.06	1.26	3.37	0.004^a
Day 57		Erythema	2.03	1.01	4.09	0.047^a

Factors predicting the response to ingenol mebutate 0.015% therapy.

^a

P < 0.05. OR: Odds ratio; LSR: Local skin reaction.